Editor of Patient Care Online.
Postpartum Hormonal Contraceptives Up Depression Risk by 50%: Daily Dose
Your daily dose of the clinical news you may have missed.
Bringing PPD Screening to the Forefront of Maternal Health: A Q&A with Joy Baker, MD
ACOG 2025: Joy Baker, MD, discusses the urgent need to prioritize postpartum depression screening, normalize mental health in prenatal care, and strengthen continuity between OB-GYN and primary care.
ctDNA Blood Test Showed High Sensitivity, Specificity for Colorectal Cancer but Poor Sensitivity for Advanced Precancerous Neoplasia
A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.
OASIS-4 Trial: Elinzanetant Reduces Frequency of Vasomotor Symptoms Related to Endocrine Therapy for HR-Positive Breast Cancer
ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.
Phase 2 Dose-Finding Study of Intranasal Epinephrine Powder (NS002) Supports Development for Regulatory Submission
Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.
Novel Resorbable Sinonasal Implant Significantly Reduces Symptoms in Treatment-Resistant CRS
Lyra Pharmaceuticals designed the implant, which provides 6 months of continuous delivery of the anti-inflammatory mometasone furoate.
New-Onset T2D Tied to Higher Risk of Obesity-Related Cancer: Daily Dose
New Data on Atopic Dermatitis for Frontline Clinicians: RAD 2025 Preview
Preview of 10 new studies on managing atopic dermatitis, including biologics, treatment barriers, and innovative care strategies for clinicians.
Regeneron Phase 2b Study Shows Antibodies Help Preserve Lean Mass During Weight Loss with Semaglutide
Interim results from COURAGE trial suggest combining semaglutide with muscle-preserving antibodies significantly enhances fat loss while preserving lean mass in obesity treatment.
High-Quality Macronutrients Key to Cardiovascular Risk Reduction, Large Cohort Study Finds
Research reveals that the quality of foods in low-carb and low-fat diets significantly impacts heart health, emphasizing whole, plant-based options.
Moderna COVID-19 Vaccine mNEXSPIKE FDA-Approved Under New Eligibility Guidelines
Moderna's mRNA-1283 vaccine gains FDA approval for high-risk groups, following a significant shift in COVID-19 vaccination guidelines by federal health agencies.
Kennedy's First Pass at US Vaccine Policy: ACIP Guidance Reversed, Clinical Trials Amended, WHO Abandoned
Kennedy over 2 weeks has introduced changes in vaccination recommendations and research policy that undermine already tenuous public trust and understanding.
FDA Clears First Blood Test for Alzheimer Disease: Daily Dose
AI Model Shows Promise for Objectively Scoring Atopic Dermatitis Severity
The AI model showed high accuracy in detecting body parts and eczema areas, with strong correlation to physician assessments, researchers reported.
Coexisting Hypertension and Type 2 Diabetes in US Adults Doubled Over 2 Decades: New Study
Adults with both HTN and T2D had more than twice the risk of all-cause mortality and nearly three times the risk of cardiovascular mortality, according to new data.
Sanofi, Regeneron's IL-33 mAb Misses Primary Endpoint in Late-Stage COPD Trial
Itepekimab performed well in the phase 3 AERIFY-1 trial but fell short of anticipated outcomes in AERIFY-2, prompting further analysis after the mixed results.
AI Tool Enhances Breast Cancer Detection, Spotting Missed Tumors: Daily Dose
High-Quality Carbohydrates in Midlife Linked to Healthier Aging in Women
For every 10% increase in energy from high-quality carbohydrates, the odds of healthy aging rose by 31%, according to an analysis of data from the Nurse's Health Study.
Enobosarm Significantly Preserves Muscle Mass When Added to Semaglutide, Advances to Phase 3 Development Program
Enobosarm added to semaglutide shows promising results in preserving muscle mass while promoting fat loss in older adults, according to developer Veru, Inc.
Real-World Study Confirms Upadacitinib’s Efficacy in Crohn Disease Treatment: Daily Dose
Provider Gaps in Postpartum Depression Screening and Management Highlighted in New Study
ACOG 2025: Laxmi Gannu, MS, discusses key findings from a provider survey on postpartum depression screening practices, training gaps, and referral patterns.
Dosing Begins in Phase 2b Trial of Investigational Oral COVID-19 Vaccine Candidate
Vaxart's phase 2b trial for its oral COVID-19 vaccine follows a positive safety review and aims to enroll 10,000 participants in the US.
ASCO 2025: GLP-1 Receptor Agonists Linked to Modest Reduction in Obesity-Related Cancer Risk
GLP-1 receptor agonists showed promise in lowering obesity-related cancer risks in adults with type 2 diabetes, particularly colorectal cancer.
Alzheimer's Association, Senate Champions Refute HHS Secretary Kennedy's Misinformation Head On During Tense Budget Hearing
Senate hearing reveals tensions between scientific consensus and HHS Secretary Kennedy's claims on Alzheimer research funding and priorities.
IV Ibuprofen Cuts Postop Opioid Use by 23% in Older Adults, Study Finds
The opioid-sparing IVIB pain management strategy in adults aged 60 and older was effective in the immediate post-surgical period and associated with limited AEs.
Telehealth Reduces Antibiotic Use for Pediatric ARTIs in Primary Care: Daily Dose
Tailoring Weight Management Conversations Across a Woman’s Lifespan
Johanna Finkle, MD, outlines how clinicians can adapt weight management counseling during key stages of a woman’s life, from preconception through menopause.
FDA Advisory Panel Recommends Continued Use of Monovalent JN.1 Strain for COVID-19 Vaccines
FDA panel endorses continued use of monovalent JN.1 strain for COVID-19 vaccines, aligning with global health recommendations amid evolving variants.
Novel 5-HT2A Agonist GM-2505 Achieves 94% Remission Rate in Phase 2a MDD Trial, With Rapid and Durable Efficacy
The novel rapid-acting psychedelic agent produced antidepressant effects within 24 hours after the first infusion, with a -18.5 point change in MADRS from baseline.
Telehealth May Represent Up to 30% of US Medical Visits by 2026
Telemedicine's trajectory depends far more on future regulatory action than on health care's readiness or patient desire, according to a new report.
